Exact Mass: 577.2887
Exact Mass Matches: 577.2887
Found 494 metabolites which its exact mass value is equals to given mass value 577.2887
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Aplaviroc
Dihydroergocryptine
D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
PC(2:0/18:1(12Z)-O(9S,10R))
PC(2:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
PC(18:1(12Z)-O(9S,10R)/2:0)
PC(18:1(12Z)-O(9S,10R)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(18:1(12Z)-O(9S,10R)/2:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
PC(2:0/18:1(9Z)-O(12,13))
PC(2:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(2:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
PC(18:1(9Z)-O(12,13)/2:0)
PC(18:1(9Z)-O(12,13)/2:0) is an oxidized phosphatidylcholine (PC or GPCho). Oxidized phosphatidylcholines are glycerophospholipids in which a phosphorylcholine moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidylcholines belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PC(18:1(9Z)-O(12,13)/2:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PCs can be synthesized via three different routes. In one route, the oxidized PC is synthetized de novo following the same mechanisms as for PCs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidated acyl chains with an oxidated acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PC backbone, mainely through the action of LOX (PMID: 33329396).
Gln Lys Phe Arg
Phe Gln Arg Lys
Aplaviroc
CONFIDENCE standard compound; INTERNAL_ID 1231; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3939; ORIGINAL_PRECURSOR_SCAN_NO 3936 D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D065147 - Viral Fusion Protein Inhibitors D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D054659 - Diketopiperazines D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D044966 - Anti-Retroviral Agents C254 - Anti-Infective Agent > C281 - Antiviral Agent > C1660 - Anti-HIV Agent D065147 - Viral Fusion Protein Inhibitors > D023581 - HIV Fusion Inhibitors C308 - Immunotherapeutic Agent > C63817 - Chemokine Receptor Antagonist CONFIDENCE standard compound; INTERNAL_ID 1231; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3969; ORIGINAL_PRECURSOR_SCAN_NO 3968 CONFIDENCE standard compound; INTERNAL_ID 1231; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3955; ORIGINAL_PRECURSOR_SCAN_NO 3954 CONFIDENCE standard compound; INTERNAL_ID 1231; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3951; ORIGINAL_PRECURSOR_SCAN_NO 3949 CONFIDENCE standard compound; INTERNAL_ID 1231; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3974; ORIGINAL_PRECURSOR_SCAN_NO 3972 CONFIDENCE standard compound; INTERNAL_ID 1231; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 3966; ORIGINAL_PRECURSOR_SCAN_NO 3963 CONFIDENCE standard compound; INTERNAL_ID 1231; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8318; ORIGINAL_PRECURSOR_SCAN_NO 8316 CONFIDENCE standard compound; INTERNAL_ID 1231; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8332; ORIGINAL_PRECURSOR_SCAN_NO 8329 CONFIDENCE standard compound; INTERNAL_ID 1231; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8335; ORIGINAL_PRECURSOR_SCAN_NO 8333 CONFIDENCE standard compound; INTERNAL_ID 1231; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8354; ORIGINAL_PRECURSOR_SCAN_NO 8352 CONFIDENCE standard compound; INTERNAL_ID 1231; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8356; ORIGINAL_PRECURSOR_SCAN_NO 8354 CONFIDENCE standard compound; INTERNAL_ID 1231; DATASET 20200303_ENTACT_RP_MIX504; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 8364; ORIGINAL_PRECURSOR_SCAN_NO 8361
Cys His Arg Tyr
Cys His Tyr Arg
Cys Asn Arg Trp
Cys Asn Trp Arg
Cys Arg His Tyr
Cys Arg Asn Trp
Cys Arg Trp Asn
Cys Arg Tyr His
Cys Trp Asn Arg
Cys Trp Arg Asn
Cys Tyr His Arg
Cys Tyr Arg His
Glu Phe Pro Trp
Glu Phe Trp Pro
Glu His His Arg
Glu His Arg His
Glu Ile Met Trp
Glu Ile Trp Met
Glu Leu Met Trp
Glu Leu Trp Met
Glu Met Ile Trp
Glu Met Leu Trp
Glu Met Trp Ile
Glu Met Trp Leu
Glu Pro Phe Trp
Glu Pro Trp Phe
Glu Arg His His
Glu Trp Phe Pro
Glu Trp Ile Met
Glu Trp Leu Met
Glu Trp Met Ile
Glu Trp Met Leu
Glu Trp Pro Phe
Phe Glu Pro Trp
Phe Glu Trp Pro
Phe Phe His Lys
Phe Phe His Gln
Phe Phe Lys His
Phe Phe Gln His
Phe His Phe Lys
Phe His Phe Gln
Phe His Lys Phe
Phe His Gln Phe
Phe Ile Ile Trp
Phe Ile Leu Trp
Phe Ile Trp Ile
Phe Ile Trp Leu
Phe Lys Phe His
Phe Lys His Phe
Phe Lys Gln Arg
Phe Lys Arg Gln
Phe Leu Ile Trp
Phe Leu Leu Trp
Phe Leu Trp Ile
Phe Leu Trp Leu
Phe Pro Glu Trp
Phe Pro Trp Glu
Phe Gln Phe His
Phe Gln His Phe
Phe Gln Lys Arg
Phe Gln Gln Arg
Phe Gln Arg Gln
Phe Arg Lys Gln
Phe Arg Gln Lys
Phe Arg Gln Gln
Phe Trp Glu Pro
Phe Trp Ile Ile
Phe Trp Ile Leu
Phe Trp Leu Ile
Phe Trp Leu Leu
Phe Trp Pro Glu
His Cys Arg Tyr
His Cys Tyr Arg
His Glu His Arg
His Glu Arg His
His Phe Phe Lys
His Phe Phe Gln
His Phe Lys Phe
His Phe Gln Phe
His His Glu Arg
His His Arg Glu
His His Val Trp
His His Trp Val
His Lys Phe Phe
His Lys Met Tyr
His Lys Tyr Met
His Met Lys Tyr
His Met Tyr Lys
His Gln Phe Phe
His Arg Cys Tyr
His Arg Glu His
His Arg His Glu
His Arg Tyr Cys
His Val His Trp
His Val Trp His
His Trp His Val
His Trp Val His
His Tyr Cys Arg
His Tyr Lys Met
His Tyr Met Lys
His Tyr Arg Cys
Ile Glu Met Trp
Ile Glu Trp Met
Ile Phe Ile Trp
Ile Phe Leu Trp
Ile Phe Trp Ile
Ile Phe Trp Leu
Ile Ile Phe Trp
Ile Ile Trp Phe
Ile Leu Phe Trp
Ile Leu Trp Phe
Ile Met Glu Trp
Ile Met Trp Glu
Ile Pro Trp Tyr
Ile Pro Tyr Trp
Ile Trp Glu Met
Ile Trp Phe Ile
Ile Trp Phe Leu
Ile Trp Ile Phe
Ile Trp Leu Phe
Ile Trp Met Glu
Ile Trp Pro Tyr
Ile Trp Tyr Pro
Ile Tyr Pro Trp
Ile Tyr Trp Pro
Lys Phe Phe His
Lys Phe His Phe
Lys Phe Gln Arg
Lys Phe Arg Gln
Lys His Phe Phe
Lys His Met Tyr
Lys His Tyr Met
Lys Met His Tyr
Lys Met Asn Trp
Lys Met Trp Asn
Lys Met Tyr His
Lys Asn Met Trp
Lys Asn Trp Met
Lys Gln Phe Arg
Lys Gln Arg Phe
Lys Arg Phe Gln
Lys Arg Gln Phe
Lys Trp Met Asn
Lys Trp Asn Met
Lys Tyr His Met
Lys Tyr Met His
Leu Glu Met Trp
Leu Glu Trp Met
Leu Phe Ile Trp
Leu Phe Leu Trp
Leu Phe Trp Ile
Leu Phe Trp Leu
Leu Ile Phe Trp
Leu Ile Trp Phe
Leu Leu Phe Trp
Leu Leu Trp Phe
Leu Met Glu Trp
Leu Met Trp Glu
Leu Pro Trp Tyr
Leu Pro Tyr Trp
Leu Trp Glu Met
Leu Trp Phe Ile
Leu Trp Phe Leu
Leu Trp Ile Phe
Leu Trp Leu Phe
Leu Trp Met Glu
Leu Trp Pro Tyr
Leu Trp Tyr Pro
Leu Tyr Pro Trp
Leu Tyr Trp Pro
Met Glu Ile Trp
Met Glu Leu Trp
Met Glu Trp Ile
Met Glu Trp Leu
Met His Lys Tyr
Met His Tyr Lys
Met Ile Glu Trp
Met Ile Trp Glu
Met Lys His Tyr
Met Lys Asn Trp
Met Lys Trp Asn
Met Lys Tyr His
Met Leu Glu Trp
Met Leu Trp Glu
Met Asn Lys Trp
Met Asn Trp Lys
Met Trp Glu Ile
Met Trp Glu Leu
Met Trp Ile Glu
Met Trp Lys Asn
Met Trp Leu Glu
Met Trp Asn Lys
Met Tyr His Lys
Met Tyr Lys His
Asn Cys Arg Trp
Asn Cys Trp Arg
Asn Lys Met Trp
Asn Lys Trp Met
Asn Met Lys Trp
Asn Met Trp Lys
Asn Arg Cys Trp
Asn Arg Trp Cys
Asn Trp Cys Arg
Asn Trp Lys Met
Asn Trp Met Lys
Asn Trp Arg Cys
Pro Glu Phe Trp
Pro Glu Trp Phe
Pro Phe Glu Trp
Pro Phe Trp Glu
Pro Ile Trp Tyr
Pro Ile Tyr Trp
Pro Leu Trp Tyr
Pro Leu Tyr Trp
Pro Trp Glu Phe
Pro Trp Phe Glu
Pro Trp Ile Tyr
Pro Trp Leu Tyr
Pro Trp Tyr Ile
Pro Trp Tyr Leu
Pro Tyr Ile Trp
Pro Tyr Leu Trp
Pro Tyr Trp Ile
Pro Tyr Trp Leu
Gln Phe Phe His
Gln Phe His Phe
Gln Phe Lys Arg
Gln Phe Gln Arg
Gln Phe Arg Lys
Gln Phe Arg Gln
Gln His Phe Phe
Gln Lys Arg Phe
Gln Gln Phe Arg
Gln Gln Arg Phe
Gln Arg Phe Lys
Gln Arg Phe Gln
Gln Arg Lys Phe
Gln Arg Gln Phe
Arg Cys His Tyr
Arg Cys Asn Trp
Arg Cys Trp Asn
Arg Cys Tyr His
Arg Glu His His
Arg Phe Lys Gln
Arg Phe Gln Lys
Arg Phe Gln Gln
Arg His Cys Tyr
Arg His Glu His
Arg His His Glu
Arg His Tyr Cys
Arg Lys Phe Gln
Arg Lys Gln Phe
Arg Asn Cys Trp
Arg Asn Trp Cys
Arg Gln Phe Lys
Arg Gln Phe Gln
Arg Gln Lys Phe
Arg Gln Gln Phe
Arg Trp Cys Asn
Arg Trp Asn Cys
Arg Tyr Cys His
Arg Tyr His Cys
Val His His Trp
Val His Trp His
Val Trp His His
Trp Cys Asn Arg
Trp Cys Arg Asn
Trp Glu Phe Pro
Trp Glu Ile Met
Trp Glu Leu Met
Trp Glu Met Ile
Trp Glu Met Leu
Trp Glu Pro Phe
Trp Phe Glu Pro
Trp Phe Ile Ile
Trp Phe Ile Leu
Trp Phe Leu Ile
Trp Phe Leu Leu
Trp Phe Pro Glu
Trp His His Val
Trp His Val His
Trp Ile Glu Met
Trp Ile Phe Ile
Trp Ile Phe Leu
Trp Ile Ile Phe
Trp Ile Leu Phe
Trp Ile Met Glu
Trp Ile Pro Tyr
Trp Ile Tyr Pro
Trp Lys Met Asn
Trp Lys Asn Met
Trp Leu Glu Met
Trp Leu Phe Ile
Trp Leu Phe Leu
Trp Leu Ile Phe
Trp Leu Leu Phe
Trp Leu Met Glu
Trp Leu Pro Tyr
Trp Leu Tyr Pro
Trp Met Glu Ile
Trp Met Glu Leu
Trp Met Ile Glu
Trp Met Lys Asn
Trp Met Leu Glu
Trp Met Asn Lys
Trp Asn Cys Arg
Trp Asn Lys Met
Trp Asn Met Lys
Trp Asn Arg Cys
Trp Pro Glu Phe
Trp Pro Phe Glu
Trp Pro Ile Tyr
Trp Pro Leu Tyr
Trp Pro Tyr Ile
Trp Pro Tyr Leu
Trp Arg Cys Asn
Trp Arg Asn Cys
Trp Val His His
Trp Tyr Ile Pro
Trp Tyr Leu Pro
Trp Tyr Pro Ile
Trp Tyr Pro Leu
Tyr Cys His Arg
Tyr Cys Arg His
Tyr His Cys Arg
Tyr His Lys Met
Tyr His Met Lys
Tyr His Arg Cys
Tyr Ile Pro Trp
Tyr Ile Trp Pro
Tyr Lys His Met
Tyr Lys Met His
Tyr Leu Pro Trp
Tyr Leu Trp Pro
Tyr Met His Lys
Tyr Met Lys His
Tyr Pro Ile Trp
Tyr Pro Leu Trp
Tyr Pro Trp Ile
Tyr Pro Trp Leu
Tyr Arg Cys His
Tyr Arg His Cys
Tyr Trp Ile Pro
Tyr Trp Leu Pro
Tyr Trp Pro Ile
Tyr Trp Pro Leu
Epicriptine
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist
N-(2-(((3S,4S)-1-(4-(BENZO[D][1,3]DIOXOL-5-YL)-4-HYDROXYCYCLOHEXYL)-4-ETHOXYPYRROLIDIN-3-YL)AMINO)-2-OXOETHYL)-3-(TRIFLUOROMETHYL)BENZAMIDE
ETHYL 2-((5-(4-(TERT-BUTOXYCARBONYL)PIPERAZIN-1-YL)PYRIDIN-2-YL)AMINO)-8-CYCLOPENTYL-5-METHYL-7-OXO-7,8-DIHYDROPYRIDO[2,3-D]PYRIMIDINE-6-CARBOXYLATE
tert-butyl 2-((4S,6S)-6-((E)-2-(4-(4-fluorophenyl)-6-isopropyl-2-(N-methylmethylsulfonamido)pyrimidin-5-yl)vinyl)-2,2-dimethyl-1,3-dioxan-4-yl)acetate
Dihydroergocryptine
C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D015259 - Dopamine Agents > D018491 - Dopamine Agonists D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents
(E)-N-(4-((4-Ethylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-(2-(4-methoxy-1H-pyrrolo[2,3-b]pyridin-5-yl)vinyl)-4-methylbenzamide
HG6-64-1 is a potent and selective B-Raf inhibitor extracted from patent WO 2011090738 A2, example 9 (XI-1); has a IC50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells.
[(2R)-3-acetyloxy-2-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
[(2R)-2-acetyloxy-3-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
Dihydro-beta-ergocryptine
beta-Ergocryptine in which a single bond replaces the double bond between positions 9 and 10.
N-[(3S,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-(methylaminomethyl)-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
N-[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-(1-methyl-3-indolyl)acetamide
N-[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-(1-methyl-3-indolyl)acetamide
N-[(2S,3R)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(3R,9S,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-(methylaminomethyl)-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
N-[(2S,3S)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(3R,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-(methylaminomethyl)-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
(1S)-1-(hydroxymethyl)-7-methoxy-N-(4-methoxyphenyl)-2-[2-(4-morpholinyl)-1-oxoethyl]-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
N-[(3S,9R,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-(methylaminomethyl)-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
N-[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-(1-methyl-3-indolyl)acetamide
N-[(3R,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-(methylaminomethyl)-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
N-[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-(1-methyl-3-indolyl)acetamide
N-[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-(1-methyl-3-indolyl)acetamide
N-[(2S,3R)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(3R,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-(methylaminomethyl)-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
N-[(2R,3R)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-(1-methyl-3-indolyl)acetamide
N-[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-(1-methyl-3-indolyl)acetamide
N-[(3R,9R,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-(methylaminomethyl)-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
N-[(3S,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-(methylaminomethyl)-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
N-[(3S,9R,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-(methylaminomethyl)-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
N-[(3S,9R,10R)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-(methylaminomethyl)-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
N-[(2R,3R)-2-[[[[(3,5-dimethyl-4-isoxazolyl)amino]-oxomethyl]-methylamino]methyl]-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-phenylacetamide
N-[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-2-[[methyl-[oxo-(propan-2-ylamino)methyl]amino]methyl]-6-oxo-2,3,4,7-tetrahydro-1,5-benzoxazonin-9-yl]-2-(1-methyl-3-indolyl)acetamide
N-[(3S,9S,10S)-12-[(2R)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-(methylaminomethyl)-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
N-[(3R,9S,10R)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-(methylaminomethyl)-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
N-[(3R,9S,10S)-12-[(2S)-1-hydroxypropan-2-yl]-3,10-dimethyl-9-(methylaminomethyl)-13-oxo-2,8-dioxa-12-azabicyclo[12.4.0]octadeca-1(14),15,17-trien-16-yl]-4-methoxybenzenesulfonamide
(1R)-1-(hydroxymethyl)-7-methoxy-N-(4-methoxyphenyl)-2-[2-(4-morpholinyl)-1-oxoethyl]-1-spiro[3,9-dihydro-1H-pyrido[3,4-b]indole-4,4-piperidine]carboxamide
2-amino-3-[[3-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-2-hydroxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[hydroxy-[2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-propanoyloxypropoxy]phosphoryl]oxypropanoic acid
2-amino-3-[[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-pentanoyloxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
2-amino-3-[[3-butanoyloxy-2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxypropanoic acid
3-[[3-acetyloxy-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxy-2-aminopropanoic acid
dihydro-alpha-ergocryptine
alpha-Ergocryptine in which a single bond replaces the double bond between positions 9 and 10.